Google’s Megan Smith tapped as new U.S. CTO

Laura Pedulli | | Health Exec | Precision Medicine

President Obama has appointed a Google executive, Megan Smith, to join his administration as chief technology officer.

Smith, who most recently served as vice president of new business development at Google, is the third person to take on this role since the administration created the position in April 2009. Previously, Aneesha Chopra and Todd Park served as the U.S. CTO.

“Megan has spent her career leading talented teams and taking cutting-edge technology and innovation initiatives from concept to design to deployment,” said President Obama in a statement. “I am confident that in her new role … she will put her long record of leadership and exceptional skills to work on behalf of the American people.”

The White House also announced that Alexander Macgillivray will serve as deputy U.S. CTO. Macgillivray is an internationally recognized expert in technology law and policy. He most recently served as general counsel and head of public policy at Twitter from 2009 to 2013, according to the White House.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.